OVID Ovid Therapeutics Inc.

NEUTRAL Impact: 2/10 8-K
Horizon immediate Filed Jun 3, 2026 Processed 3d 11h ago SEC 0001628280-26-040038
8-K context-dependent: Items 5.02

Price Chart

Loading chart...

Executive Summary

Ovid Therapeutics appointed Dr. Anna Greka, a Harvard Medical School professor and Broad Institute executive, as a Class III director effective June 15, 2026, expanding the board to seven members. This is a routine board appointment with no material financial impact.

Actionable Insight

Routine board appointment with no immediate trading implications. Monitor for any future scientific or strategic developments tied to Dr. Greka's expertise in kidney disease and biotech venture advisory.

Key Facts

  • Board expanded from six to seven directors effective June 15, 2026
  • Dr. Anna Greka appointed as Class III director with term expiring at 2029 annual meeting
  • Dr. Greka also appointed to Compensation Committee and Science and Technology Committee
  • Dr. Greka is Professor of Medicine at Harvard Medical School and holds leadership roles at Broad Institute
  • Compensation follows standard non-employee director policy; standard indemnification agreement entered

Financial Impact

No financial figures disclosed; compensation is standard non-employee director policy

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-040038
Document: 0001628280-26-040038-index-headers.html0001628280-26-040038
Document: 0001628280-26-040038-index.html0001628280-26-040038
Document: 0001628280-26-040038.txt0001628280-26-040038
9 reports for OVID
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for OVID — sortable, filterable
Type Now
Jun 3, 2026
3d ago
8-K
NEUTRAL ★ 2/10
awaiting T+5
May 12, 2026
25d ago
Press Release
MIXED ★ 6/10
$2.87 $2.41▼ −16.03%▼ −16.11%$2.40 (−16.38%)
Apr 27, 2026
5w ago
EFFECT
NEUTRAL ★ 4/10
$2.69 $2.93▲ +8.92%▲ +8.52%$2.40 (−10.78%)
Apr 21, 2026
6w ago
S-3
NEUTRAL ★ 4/10
$2.66 $2.71▲ +1.69%▲ +1.64%$2.40 (−9.77%)
Apr 20, 2026
6w ago
8-K
BULLISH ★ 6/10
$2.89 $2.69▼ −6.92%▼ −7.83%$2.40 (−16.96%)
Mar 18, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$2.30 $2.40▲ +4.35%▲ +5.06%$2.40 (+4.35%)
Mar 18, 2026
11w ago
Press Release
MIXED ★ 6/10
$2.30 $2.40▲ +4.35%▲ +5.06%$2.40 (+4.35%)
Mar 18, 2026
11w ago
Press Release
NEUTRAL ★ 5/10
$2.30 $2.40▲ +4.35%▲ +5.06%$2.40 (+4.35%)
Feb 23, 2026
14w ago
Insider Cluster
NEUTRAL ★ 2/10
$1.45 $1.66▲ +14.48%▲ +13.86%$2.40 (+65.52%)
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (14h 48m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access